Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03692715
Other study ID # CLUE
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date September 27, 2018
Est. completion date December 31, 2024

Study information

Verified date October 2021
Source Clinical Urology and Epidemiology Working Group
Contact Kari AO Tikkinen, MD PhD
Phone +358-40-6510530
Email kari.tikkinen@helsinki.fi
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a two arm, double blind RCT comparing the use of a single dose ciprofloxacin prior to SWL to saline alone. The multicenter trial will be conducted with a pragmatic emphasis including both high volume and low volume sites internationally.


Description:

This is a two arm, double blind randomized controlled trial (RCT) comparing the use of a single dose ciprofloxacin prior to shock wave lithotripsy (SWL) to placebo. The multicenter trial will be conducted with a pragmatic emphasis including both high volume and low volume sites internationally. Eligibility criteria include patients older than 18 years presenting for SWL who do not meet one of the pre-defined exclusion criteria (outlined below). Eligible patients will provide written informed consent. Patients will undergo central randomization, which will be accessed by phone or internet. Un-blinding will occur only once statistical analysis is complete. Patients will undergo SWL using standard procedures at the participating center. Participants will asked to provide a pre-procedure study questionnaire, a modified International Prostate Symptom Score (IPSS) questionnaire and a urine sample for analysis prior to SWL and follow-up. Follow-up questionnaires and a requisition for urine culture will be provided in a pre-stamped, self-addressed envelope along with instructions to return both culture and questionnaires to their participating center at 7-14 days post-SWL. If the follow-up questionnaire has not been received by post-operative day 10 patients will receive a reminder phone call. A second envelope will be sent containing a requisition for urine culture and follow-up questionnaire when necessary. Alternatively, if a 2 week follow-up is conducted at the participating site then data-forms can be completed and collected at that time. In the event that a urine culture was not submitted 7 days post-operatively, one can be collected up to 14 days post-op. Additional clinical parameters such as presence of double J, stone characteristics and renal insufficiency will be recorded at the time of SWL by the dedicated research staff at the participating center. Data acquisition and occurrence of outcomes will be monitored continuously with scheduled audits. Primary and secondary outcomes are outlined below. The power calculation for this protocol was performed using Stata v.10.1 (StataCorp, College Station, TX). The investigators used the American Urological Association Best Practice Statement on antibiotic prophylaxis to estimate a 60% relative risk reduction with treatment arm. Therefore to achieve a power of 90% with a significance level of p<0.05, 661 patients will need to be recruited in each arm for a total of 1,322 patients. Accounting for 10% loss to follow-up, the total required will be 1454, or approximately 1500 patients. Assuming that 25% of patients screened will either refuse to be randomized or will meet one of the pre-defined exclusion criteria, a minimum of 2000 patients will need to be screened in order to randomize 1500 patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 1500
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients older than 18 years presenting for SWL who do not meet one of the pre-defined exclusion criteria. Exclusion Criteria: - Pre-SWL urine analysis positive for nitrites - Pre-SWL urine culture reveals >10e5 Colony Forming Unit/ml of bacteria (positive urine culture) - Taking antibiotics for Urinary Tract Infection (UTI) or other cause - Suspected struvite stone (based on previous stone analysis, or partial staghorn) - Presence of nephrostomy tube - Requiring cystoscopy and ureteral stent insertion on the day of SWL - Presence of Foley catheter or patient on regular clean intermittent catheterization (CIC) - Presence of urinary diversion (ie: ileal conduit) - History of urosepsis prior to SWL - Known allergic reaction to trial antibiotic - Previous randomization in this trial - In the opinion of the independent treating urologist, it is not in the patient's best interest to participate

Study Design


Intervention

Drug:
Ciprofloxacin
Oral or intravenous ciprofloxacin prior to shockwave lithotripsy.
Placebo
identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.

Locations

Country Name City State
Brazil Hospital Sao Luiz São Paulo
Canada Western University Hospital London Ontario
Canada University of Sherbrooke Sherbrooke Quebec
Finland Helsinki University Hospital Helsinki
Indonesia Universitas Indonesia - Cipto Mangunkusumo Hospital Jakarta
Iran, Islamic Republic of Tabriz University of Medical Science Tabriz
Ireland Tallaght University Hospital Dublin
Russian Federation St Petersburg State Pavlov Medical University Saint Petersburg
Saudi Arabia King Abdulaziz University Jeddah
Switzerland Department of Urology, University Hospital Basel Basel

Sponsors (12)

Lead Sponsor Collaborator
Clinical Urology and Epidemiology Working Group Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Dr Cipto Mangunkusumo General Hospital, Helsinki University Central Hospital, Hospital Sao Luiz, King Abdulaziz University, St. Petersburg State Pavlov Medical University, Tabriz University of Medical Sciences, Tallaght University Hospital, University Hospital, Basel, Switzerland, University of Helsinki, University of Western Ontario, Canada

Countries where clinical trial is conducted

Brazil,  Canada,  Finland,  Indonesia,  Iran, Islamic Republic of,  Ireland,  Russian Federation,  Saudi Arabia,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite outcome including positive urine culture, symptoms of cystitis, pyelonephritis or urosepsis The composite outcome with be assessed as a dichotomous variable. The presence of Positive post-SWL urine culture (= 10e5 Colony Forming Unit/ ml), with either one or more of symptoms of cystitis (defined as new onset burning sensation or pain with voiding, frequency, urgency), or pyelonephritis or urosepsis (hospital admission with fever =38.5 C) will be considered as an event. 7-14 days post-shockwave lithotripsy
Secondary Bacteriuria defined as = 100000 Colony Forming Unit/ml Bacteriuria will be assessed as a dichotomous variable with presence of is =100000 Colony Forming Unit/ml will be considered as an event 7-14 days post-shockwave lithotripsy
Secondary Symptoms of cystitis defined as new onset burning sensation or pain with voiding, frequency, urgency Symptoms of cystitis will be considered as a dichotomous variable with new onset burning sensation or pain with voiding, frequency, urgency will be considered an event 7-14 days post-shockwave lithotripsy
Secondary Pyelonephritis or urosepsis defined as Hospital admission with fever =38.5 Celsius Pyelonephritis or urosepsis will be assessed as a dichotomous variable with Hospital admission with fever =38.5 Celsius will be considered as an event 7-14 days post-shockwave lithotripsy
Secondary Change in International Prostate Symptom Score (IPSS) total score (0-35, higher score indicates worse outcome) Change in total value of IPSS score will be assessed as a continuous variable with a range from 0-35 with higher scores indicating more severe symptoms. This score is calculated by summation of individual component scores (0-5) across 7 domains 14 days post-shockwave lithotripsy
Secondary Individual components of International Prostate Symptom Score (0-7 per domain, with higher score indicating worse outcome) Individual IPSS domains will be assessed as continuous variables and include incomplete emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Higher scores as considered as more severe symptoms 14 days post-shockwave lithotripsy
Secondary Pain scale determined on a range of 0-5 with higher score indicating worse outcome Pain scale will be assessed as a continuous variable. The scale will be elicited by asking In the past week, how often have you had burning or discomfort with urination? Higher score is considered as more severe symptoms 14 days post-shockwave lithotripsy
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04746378 - PRedictive Accuracy of Initial Stone Burden Evaluation.
Recruiting NCT05100017 - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure N/A
Completed NCT02547805 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days Phase 2
Completed NCT02289755 - Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria Phase 2
Completed NCT01650935 - Comparison of DASH With Oxalate Restricted Diet on Urine in Recurrent Stone Formers With Hyperoxaluria N/A
Completed NCT01690039 - Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis
Completed NCT01295879 - Vitamin D Repletion in Stone Formers With Hypercalciuria Phase 4
Recruiting NCT05014178 - Kidney Sodium Functional Imaging
Not yet recruiting NCT06199102 - The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants. N/A
Recruiting NCT04367155 - Efficacy of Tranexamic Acid on Blood Loss During Percutaneous Nephrolithotomy. N/A
Recruiting NCT04374188 - Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy N/A
Recruiting NCT05701098 - SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD) N/A
Recruiting NCT04389853 - Mini-PNCL vs fURS in Management of Nephrolithiasis N/A
Completed NCT03348228 - Effect of Hydroxycitrate on Urine Chemistry N/A
Completed NCT05350423 - Trial Assessing Renal Damage During Ureteroscopy N/A
Completed NCT03454139 - Subcostal TAP Block For Percutaneous Nephrolithotomy N/A
Recruiting NCT02279927 - Prospective Comparison Between Different Laser Settings for Ureteral \ Kidney Stones Treatment During Ureteroscopy N/A
Completed NCT02276924 - Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors N/A
Completed NCT00159393 - Percutaneous Nephrolithotomy: A Registry and Database
Completed NCT02878148 - Conditional Imaging Prescription Strategy for Exploration of Acute Uncomplicated Renal Colic N/A